To overview the present global burden of pneumococcal disease is important because new
preventive measures such as the pneumococcal conjugate vaccine 13 are currently being …

Pneumococcal disease can be divided into invasive disease, ie when bacteria are detected
in normally sterile body fluids, and noninvasive disease. Pneumococcal disease occurs …

Clin Microbiol Infect 2012; 18 (Suppl. 5): 7–14 Abstract Streptococcus pneumoniae causes
different types of acute, invasive and non‐invasive clinical infections, being the most …

Background. Although it is widely accepted that adults with immunocompromising conditions
are at greatly increased risk of pneumococcal infection, the extent of risk among …

The burden of pneumococcal disease among adults in developed countries is neither widely
known nor appreciated. The incidence of pneumococcal pneumonia is uncertain because a …

Pneumococcal polysaccharide vaccine has been licensed for use in the United States for>
30 years, and two-thirds of the elderly population in the United States have received this …

Background Incidence, manifestations and case-fatality rate (CFR) of invasive
pneumococcal disease (IPD) vary with age and comorbidities. New vaccines, changing age …

Pneumococcal disease constitutes a major global health problem. Adults aged over 50
years and younger adults with specific chronic health conditions are at risk for invasive …

Use of the pneumococcal conjugate vaccines among children in the US since 2000 has
dramatically reduced pneumococcal disease burden among adults. Significant vaccine …

Streptococcus pneumoniae–the pneumococcus–affects children and adults worldwide.
Invasive pneumococcal disease, including pneumonia, meningitis and bacteraemia, has …